Total Payments
$16,054
2024 Payments
$2,572
Companies
62
Transactions
945
Medicare Patients
2,945
Medicare Billing
$630,872
Payment Breakdown by Category
Food & Beverage$15,693 (97.8%)
Education$250.94 (1.6%)
Other$109.68 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,693 | 931 | 97.8% |
| Education | $250.94 | 7 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $109.68 | 7 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,772 | 96 | $0 (2024) |
| Lundbeck LLC | $1,236 | 63 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $1,179 | 83 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $1,056 | 67 | $0 (2024) |
| UCB, Inc. | $869.40 | 43 | $0 (2024) |
| Biogen, Inc. | $835.45 | 104 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $713.73 | 43 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $680.67 | 24 | $0 (2024) |
| Amgen Inc. | $639.52 | 46 | $0 (2023) |
| Allergan, Inc. | $527.64 | 39 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,572 | 105 | ABBVIE INC. ($688.43) |
| 2023 | $2,223 | 92 | ABBVIE INC. ($337.56) |
| 2022 | $2,029 | 99 | ABBVIE INC. ($332.37) |
| 2021 | $1,690 | 104 | AbbVie Inc. ($301.76) |
| 2020 | $1,413 | 103 | Upsher-Smith Laboratories LLC ($228.24) |
| 2019 | $1,609 | 98 | Novartis Pharmaceuticals Corporation ($246.70) |
| 2018 | $2,364 | 176 | Biogen, Inc. ($249.04) |
| 2017 | $2,153 | 168 | Teva Pharmaceuticals USA, Inc. ($305.92) |
All Payment Transactions
945 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $33.14 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: Neuropsychiatry | ||||||
| 12/11/2024 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Neuroscience | ||||||
| 12/10/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: RETT SYNDROME | ||||||
| 12/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.17 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.95 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $28.80 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: EPILEPSY | ||||||
| 11/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.42 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/12/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: NEUROLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $34.50 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $32.73 | General |
| Category: Neuropsychiatry | ||||||
| 11/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: PAIN | ||||||
| 10/28/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.70 | General |
| Category: NEUROLOGY | ||||||
| 10/23/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: Immunology | ||||||
| 10/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $6.04 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: Central Nervous System | ||||||
| 10/17/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $22.74 | General |
| 10/09/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.76 | General |
| Category: NEUROSCIENCE | ||||||
| 10/07/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Adenosine A2A Receptors | ||||||
| 10/01/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: NEUROLOGY | ||||||
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 651 | 16,426 | $470,583 | $157,855 |
| 2022 | 12 | 686 | 13,087 | $446,353 | $143,922 |
| 2021 | 12 | 791 | 13,790 | $490,422 | $162,829 |
| 2020 | 12 | 817 | 15,829 | $529,017 | $166,266 |
Total Patients
2,945
Total Services
59,132
Medicare Billing
$630,872
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 24 | 15,610 | $187,320 | $77,257 | 41.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 95 | 157 | $56,677 | $18,286 | 32.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 105 | 105 | $61,110 | $15,611 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 99 | 161 | $43,309 | $13,183 | 30.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 158 | 161 | $37,835 | $11,782 | 31.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 24 | 80 | $29,360 | $8,358 | 28.5% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 55 | 57 | $21,033 | $5,283 | 25.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $12,800 | $3,180 | 24.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $8,547 | $2,176 | 25.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 14 | 18 | $4,842 | $1,537 | 31.7% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 31 | 31 | $7,750 | $1,202 | 15.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 20 | 12,200 | $146,400 | $59,455 | 40.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 92 | 172 | $62,092 | $20,602 | 33.2% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 108 | 109 | $63,438 | $15,796 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 195 | $52,455 | $14,547 | 27.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 158 | 162 | $38,070 | $11,964 | 31.4% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 20 | 61 | $22,387 | $6,365 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $15,360 | $4,727 | 30.8% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 49 | 51 | $18,819 | $4,561 | 24.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 26 | 27 | $4,968 | $1,408 | 28.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $5,291 | $1,276 | 24.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 17 | $4,573 | $1,223 | 26.7% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 26 | 28 | $7,000 | $1,072 | 15.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 21 | 22 | $5,500 | $925.05 | 16.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 21 | 12,800 | $153,600 | $62,995 | 41.0% |
About Dr. Mark Ramirez, M.D
Dr. Mark Ramirez, M.D is a Neurology healthcare provider based in Roseburg, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2008. The National Provider Identifier (NPI) number assigned to this provider is 1245400209.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Ramirez, M.D has received a total of $16,054 in payments from pharmaceutical and medical device companies, with $2,572 received in 2024. These payments were reported across 945 transactions from 62 companies. The most common payment nature is "Food and Beverage" ($15,693).
As a Medicare-enrolled provider, Ramirez has provided services to 2,945 Medicare beneficiaries, totaling 59,132 services with total Medicare billing of $630,872. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Roseburg, OR
- Active Since 03/06/2008
- Last Updated 09/17/2015
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1245400209
Products in Payments
- APTIOM (Drug) $1,117
- UBRELVY (Drug) $1,013
- QULIPTA (Drug) $711.52
- TYSABRI (Biological) $706.63
- VYEPTI (Biological) $657.28
- INGREZZA (Drug) $620.70
- Aimovig (Biological) $550.63
- Briviact (Drug) $537.13
- NORTHERA (Drug) $525.04
- RYTARY (Drug) $486.70
- COPAXONE (Drug) $317.02
- AUSTEDO (Drug) $307.61
- BOTOX (Biological) $302.40
- KYNMOBI (Drug) $254.87
- NURTEC ODT (Drug) $251.55
- TROKENDI XR (Drug) $246.21
- AIMOVIG (Biological) $239.07
- AUBAGIO (Drug) $236.98
- INBRIJA (Drug) $236.77
- OCREVUS (Biological) $234.13
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.